OBJECTIVES: To evaluate relationships between frailty and cognition longitudinally in adults 50 years and older with breast cancer receiving chemotherapy. DESIGN: Secondary analysis of a prospective longitudinal observational study. SETTING: University of Rochester NCI Community Oncology Research Program community oncology clinics. PARTICIPANTS: Patients with breast cancer age 50 and older receiving adjuvant/neoadjuvant chemotherapy (n = 376) and age-matched controls without cancer (n = 234). MEASUREMENTS: Frailty was assessed using a modified frailty score from self-reported assessments (weakness, exhaustion, physical activity, and gait speed). Cognition was assessed by patient report (Functional Assessment of Cancer Therapy-Cognition [FACT-Cog]) and objective measures. Frailty and cognition were measured at three time points (prechemotherapy [A1], postchemotherapy [A2], and 6 months postchemotherapy [A3]; similar time interval for controls). Linear regression models evaluated associations between frailty and cognition adjusting for covariates. RESULTS: The average age was 59 years (standard deviation = 6.4 y). At baseline, patients with cancer had a higher mean frailty score (1.21 vs .73; P < .001) and lower mean FACT-Cog score (158.4 vs 167.3; P < .001) compared with controls. Objective cognitive measures were not statistically different. Longitudinal decline in FACT-Cog between A1 and A2 (P < .05) and between A1 and A3 (P < .01) was associated with increased frailty score in patients compared with controls. Longitudinal worsening in Controlled Oral Word Association (P < .05) and Trail-Making Test (P < .01) were associated with an increase in frailty between A1 and A2 in patients compared with controls; longitudinal decline in the Delayed Match to Sample test was associated with an increase in frailty between A1 and A3 (P < .05) in patients compared with controls. This finding remained significant for a subset analysis of those aged 65 and older. CONCLUSION: In patients with breast cancer aged 50 and older, longitudinal decline in FACT-Cog and objective measures of attention and memory were associated with increased frailty during treatment and up to 6 months posttreatment. Overall, our study suggests cognition and frailty are both important factors to assess in breast cancer patients. J Am Geriatr Soc 67:928-936, 2019.
OBJECTIVES: To evaluate relationships between frailty and cognition longitudinally in adults 50 years and older with breast cancer receiving chemotherapy. DESIGN: Secondary analysis of a prospective longitudinal observational study. SETTING: University of Rochester NCI Community Oncology Research Program community oncology clinics. PARTICIPANTS: Patients with breast cancer age 50 and older receiving adjuvant/neoadjuvant chemotherapy (n = 376) and age-matched controls without cancer (n = 234). MEASUREMENTS: Frailty was assessed using a modified frailty score from self-reported assessments (weakness, exhaustion, physical activity, and gait speed). Cognition was assessed by patient report (Functional Assessment of Cancer Therapy-Cognition [FACT-Cog]) and objective measures. Frailty and cognition were measured at three time points (prechemotherapy [A1], postchemotherapy [A2], and 6 months postchemotherapy [A3]; similar time interval for controls). Linear regression models evaluated associations between frailty and cognition adjusting for covariates. RESULTS: The average age was 59 years (standard deviation = 6.4 y). At baseline, patients with cancer had a higher mean frailty score (1.21 vs .73; P < .001) and lower mean FACT-Cog score (158.4 vs 167.3; P < .001) compared with controls. Objective cognitive measures were not statistically different. Longitudinal decline in FACT-Cog between A1 and A2 (P < .05) and between A1 and A3 (P < .01) was associated with increased frailty score in patients compared with controls. Longitudinal worsening in Controlled Oral Word Association (P < .05) and Trail-Making Test (P < .01) were associated with an increase in frailty between A1 and A2 in patients compared with controls; longitudinal decline in the Delayed Match to Sample test was associated with an increase in frailty between A1 and A3 (P < .05) in patients compared with controls. This finding remained significant for a subset analysis of those aged 65 and older. CONCLUSION: In patients with breast cancer aged 50 and older, longitudinal decline in FACT-Cog and objective measures of attention and memory were associated with increased frailty during treatment and up to 6 months posttreatment. Overall, our study suggests cognition and frailty are both important factors to assess in breast cancerpatients. J Am Geriatr Soc 67:928-936, 2019.
Authors: S M Sawrie; R C Martin; R Kuzniecky; E Faught; R Morawetz; F Jamil; M Viikinsalo; F Gilliam Journal: Neurology Date: 1999-10-22 Impact factor: 9.910
Authors: P Khatri; M Babyak; C Clancy; R Davis; N Croughwell; M Newman; J G Reves; D B Mark; J A Blumenthal Journal: Health Psychol Date: 1999-05 Impact factor: 4.267
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Nancy Fugate Woods; Andrea Z LaCroix; Shelly L Gray; Aaron Aragaki; Barbara B Cochrane; Robert L Brunner; Kamal Masaki; Anne Murray; Anne B Newman Journal: J Am Geriatr Soc Date: 2005-08 Impact factor: 5.562
Authors: R J Freedman; N Aziz; D Albanes; T Hartman; D Danforth; S Hill; N Sebring; J C Reynolds; J A Yanovski Journal: J Clin Endocrinol Metab Date: 2004-05 Impact factor: 5.958
Authors: Mackenzi Pergolotti; Nicolò Matteo Luca Battisti; Lynne Padgett; Alix G Sleight; Maya Abdallah; Robin Newman; Kathleen Van Dyk; Kelley R Covington; Grant R Williams; Frederiek van den Bos; YaoYao Pollock; Elizabeth A Salerno; Allison Magnuson; Isabella F Gattás-Vernaglia; Tim A Ahles Journal: J Geriatr Oncol Date: 2019-10-14 Impact factor: 3.599
Authors: Mackenzie E Fowler; Donna Murdaugh; Christian Harmon; Mustafa Al-Obaidi; Noha Sharafeldin; Smita Bhatia; Smith Giri; Grant R Williams Journal: J Cancer Surviv Date: 2022-09-17 Impact factor: 4.062
Authors: Juhua Luo; Stephen J Carter; Elizabeth M Cespedes Feliciano; Michael Hendryx Journal: Breast Cancer Res Treat Date: 2022-03-26 Impact factor: 4.624
Authors: Emilie D Duchesneau; Selena J An; Paula D Strassle; Katherine E Reeder-Hayes; Kristalyn K Gallagher; David W Ollila; Stephanie M Downs-Canner; Philip M Spanheimer Journal: Ann Surg Oncol Date: 2022-01-17 Impact factor: 4.339
Authors: AnnaLynn M Williams; Kevin R Krull; Carrie R Howell; Pia Banerjee; Tara M Brinkman; Sue C Kaste; Robyn E Partin; Deokumar Srivastava; Yutaka Yasui; Gregory T Armstrong; Leslie L Robison; Melissa M Hudson; Kirsten K Ness Journal: J Clin Oncol Date: 2021-07-20 Impact factor: 44.544
Authors: Tim A Ahles; Elizabeth Schofield; Yuelin Li; Elizabeth Ryan; James C Root; Sunita K Patel; Katrazyna McNeal; Alexandra Gaynor; Heidi Tan; Vani Katheria; Jessica Vazquez; Tiffany Traina; Arti Hurria Journal: J Geriatr Oncol Date: 2021-08-05 Impact factor: 3.929